Antibody persistency and dynamic trend after SARS-CoV-2 infection over 8 months
Dehgani-Mobaraki, P.; Kamber Zaidi, A.; porreca, A.; Floridi, A.; Floridi, E.
Show abstract
An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 is critical for the development of diagnostic tests and vaccines. Our study aimed at the longitudinal analysis of antibody presence, persistence and its trend over a period of eight months in a group of COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and 30th of March, 2020. The subjects were divided into two groups based on disease severity: mild and moderately-severe. The MAGLUMI 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post-infection. The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians 96%
- Pulmonary function and comparative SARS-CoV-2 RBD-specific IgG antibody response among the COVID-19 recovered group 95%
- Development and Evaluation of Two Rapid Indigenous IgG-ELISA immobilized with ACE-2 Binding Peptides for Detection Neutralizing Antibodies Against SARS-CoV-2 95%
Similar papers in this journal
- Relative expression of pro-inflammatory molecules in COVID-19 patients manifested disease severities 96%
- Genomic diversity of SARS-CoV-2 in Pakistan during fourth wave of pandemic 95%
- Comprehensive genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections: a prospective, comparative cohort study 94%
Similar papers in this journal
- RIG-I has a role in immunity against Haemonchus contortus, a gastrointestinal parasite in Ovis aries- a novel report. 94%
- Mice Mucosal Leishmaniasis model shown high parasite load, increased cytotoxicity and impaired IL-10+ cells response 93%
- Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia 93%
Similar papers in this journal
- Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India 96%
- Utility of IL-6 in the diagnosis, treatment and prognosis of COVID-19 patients: A longitudinal study 95%
- Healthcare workers’ worries and Monkeypox vaccine advocacy during the first month of the WHO Monkeypox alert: Cross-sectional survey in Saudi Arabia 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.